Outset Medical Presents New Data on Home Dialysis at National Kidney Foundation Spring Meetings

Rhea-AI Summary

Outset Medical, Inc. (NASDAQ: OM) reported new data on its Tablo Hemodialysis System at the 2022 NKF Spring Clinical Meetings in Boston. A national survey showed that 72% of dialysis patients believe Tablo offers significant clinical improvements, while 77% would consider home hemodialysis. Additionally, 77% of nephrologists view Tablo as superior to existing devices, with 98% inclined to recommend it to patients. The costs associated with peritoneal dialysis (PD) failure can exceed $72,000 per patient in hospitalization, highlighting the potential cost benefits of transitioning to home hemodialysis sooner.

Positive

• 72% of dialysis patients see Tablo as a significant improvement for home hemodialysis.
• 77% of nephrologists believe Tablo outperforms existing home dialysis devices.
• 98% of nephrologists are more likely to recommend home hemodialysis with Tablo.
• Potential savings of over $72,000 per patient due to reduced hospitalizations from PD failure.

Negative

• Risks associated with the transition from PD to in-center hemodialysis, leading to potential long-term hospitalization.

Findings Show Tablo® Hemodialysis System Increases Patient and Physician Likelihood to Adopt Home Hemodialysis (HHD)

SAN JOSE, Calif.--(BUSINESS WIRE)-- Today, Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced the release of three new data sets related to home dialysis.

The scientific papers were presented during the 2022 National Kidney Foundation (NKF) Spring Clinical Meetings in Boston, Massachusetts, April 6-10. The meetings bring together renal healthcare providers, including nephrologists, nurses, technicians, social workers, dietitians, and others in the space to learn more about the newest developments in advancing kidney care.

The results shared by Outset highlight patient and nephrologist views on home hemodialysis (HHD) adoption and hidden costs of peritoneal dialysis (PD):

• A national survey of 202 dialysis patients found that 72 percent viewed the features of the Tablo Hemodialysis System as a significant clinical improvement in home hemodialysis, and 77 percent said the Tablo’s features would make them more likely to try home hemodialysis.

• A second national survey of 184 nephrologists found that 77 percent said the features of Tablo were a significant improvement over existing home hemodialysis devices and 98 percent said these features would make them more likely to recommend home hemodialysis to their patients.

• The third data set evaluated the cost of PD failure. PD failure is associated with nearly 100 percent risk of hospitalization during the 6 months preceding discontinuation. The study found that over $72,000 is spent per patient in the 3 months before and 3 months after PD failure. Further, after the transition from PD to in-center hemodialysis, hospitalizations remain higher for former PD patients over time.

“Ongoing research and continuous innovation are critical to our mission at Outset to improve the lives of those in need of kidney care,” said Dr. Michael Aragon, Chief Medical Officer of Outset. “The data Outset presented at this meeting highlights the potential advantages of Tablo to both patients and providers, and potential cost reduction benefits of earlier PD to HHD conversions when signs are present that PD is no longer producing optimal results for patients.”

The three research papers can be read in their entirety on the Outset clinical evidence page or at the Outset booth (#804) during the NKF meeting.

1. The Tablo Hemodialysis System Increases Patient Likelihood for HHD Adoption
   Authors: Tonya L. Saffer, MPH, Michael Aragon, MD, Glenn M. Chertow, MD, MPH (Poster #360)
   
   
2. Tablo Hemodialysis System Could Increase Recommendations of Home Hemodialysis for Patients
   Authors: Tonya L. Saffer, MPH, Michael Aragon, MD, Glenn M. Chertow, MD, MPH (Poster #359)
   
   
3. Hidden Costs Associated with Conversion from Peritoneal Dialysis to Hemodialysis
   Authors: Eric D. Weinhandl, PhD, Tonya L. Saffer, MPH, and Michael Aragon, MD (Poster #362)

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA-cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset’s beliefs, projections and expectations concerning, among other things, the potential impact of the research results discussed in this press release. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to differ materially from those expressed or implied in such statements. These risks and uncertainties include risks described in the Risk Factors section of Outset’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Outset disclaims any obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005470/en/

Media Contact

Nicole Shannon

Director, Marketing Communications for Outset Medical

nshannon@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

What does the latest data from Outset Medical regarding the Tablo Hemodialysis System indicate?

The latest data shows that 72% of dialysis patients and 77% of nephrologists recognize the Tablo system as a significant improvement for home hemodialysis.

How much can hospitalization costs exceed for patients transitioning from peritoneal dialysis?

The costs associated with PD failure can exceed $72,000 per patient during the three months before and after discontinuation.

When was the data on the Tablo Hemodialysis System presented?

The data was presented during the 2022 National Kidney Foundation Spring Clinical Meetings in Boston from April 6-10.

What percentage of nephrologists are likely to recommend home hemodialysis after seeing the Tablo features?

98% of nephrologists said they would be more likely to recommend home hemodialysis to patients using the Tablo system.

What is the stock symbol for Outset Medical?

The stock symbol for Outset Medical is OM.